scPharmaceuticals to Participate in Two Upcoming Investor Conferences
October 31, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing...
scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives
September 19, 2023 08:00 ET
|
scPharmaceuticals, Inc.
Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients Agency...
scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:01 ET
|
scPharmaceuticals, Inc.
Generated net FUROSCIX® revenue of $1.6 million Ended Q2 2023 with cash, cash equivalents and short-term investments of $102.9 million Company to host investor conference call and webcast today,...
scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 03, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion
August 01, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 19, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing...
scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes
June 23, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Present at the Jefferies Healthcare Conference
May 31, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...